

BSW Formulary Update – Following APC October 2021 meeting

New and Updated Prescribing Guidelines/Shared care Guideline

- [Inclisiran \(Leqvio®\) prescribing guidance for primary care.](#)
Inclisiran [for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults] has been added to BSWformulary with **GREEN TLS**. This BSW guidance summarises the background for the green TLS and explains NHSE/I's novel funding mechanism which supports prescribing of inclisiran in primary care. The guidance also links to national pathways for [statin intolerance](#) and to the [national guidance for lipid management for primary and secondary prevention of CVD](#) which we expect to be updated to include inclisiran imminently.
- [Postural hypotension: Clinical management in primary care guidance](#)
After further discussion with our local provider organisations, this document has been changed from being a shared care agreement to a prescribing guideline. This is due to contractual and commissioning issues which are being discussed.
- [Acne vulgaris: Clinical management in primary care guidance](#) Updated in line with [NG198](#). Other formulary changes related to this update include:
 - [Oral trimethoprim](#) changed from **AMBER** to **GREEN TLS** for off-label use in acne
 - [Benzoyl peroxide/clindamycin 3%/1%](#) strength gel (Duac®) added in addition to 5%/1%
 - [Azelaic acid cream 20%](#) (Skinoren®) added in addition to 15% gel (Finacea)
- [SCA topical testosterone for low libido in menopause in adult women on HRT](#) Minor update now includes details on Testim® brand as an option as well as Tostran® and Testogel®.

New additions to the BSWformulary

- [Melatonin for cluster headaches](#) – new indication added to formulary with **RED TLS**. This is a recognised, but unlicensed indication and prescribing of melatonin for cluster headache should be retained by the Specialist.
- [Multistix 8 SG](#) – added to formulary with **RED TLS**. Note these are **not in the Drug Tariff and not available for prescribing on FP10**. Patients can self-purchase OTC.
- [Donepezil orodispersible tablet \(sugar free\) 5mg](#) – added to formulary only for use in swallowing difficulties. Note that in primary care, 10mg orodispersible tablets are ~5 times the cost of 5mg tablets. Prescribe 2 x 5mg orodispersible tabs to achieve 10mg dose.

Aligned on BSWformulary

- [Dantrolene oral capsules](#) – aligned with **AMBER TLS**

Other BSWformulary website updates

- [Emerade 300microgram and 500microgram adrenaline auto injector \(AAI\)](#) – are being re-supplied to the market (HCP communication [here](#)) so Emerade® is reinstated to BSWformulary as an option alongside Epipen® and Jext®. Emerade® is the only AAI available in 500microgram strength. **Prescribe by brand as AAI technique is device specific**; patients should receive the AAI they have been trained to use. Please also see the MHRA Drug Safety Update [Adrenaline auto-injectors: reminder for prescribers to support safe and effective use](#)
- [Diazepam 2.5mg rectal solution has been discontinued](#) but 5mg and 10mg strengths remain available.
- [Ivermectin 1% cream](#) – 45g pack size added to existing entry; 30g pack size being phased out by manufacturer.

What the BSW CCG formulary team are currently working on

- Aligning **alfentanil 500micrograms in 1mL** (available as 1mg/2ml and 5mg/10ml ampoules) with an **AMBER TLS** across BSW when used for palliative care indications on the recommendation of a Specialist. We are producing guidance to support safe prescribing.
- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSWformulary across primary and secondary care.
- Working with AWP on an oral antipsychotic SCA.
- Reviewing the national SCA consultations by RMOC.
- Reviewing COPD guidance for primary care.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net